| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019640272 |
| P356 | DOI | 10.1007/S00439-006-0186-1 |
| P3181 | OpenCitations bibliographic resource ID | 5081572 |
| P698 | PubMed publication ID | 16724231 |
| P50 | author | Markus Riessland | Q56718153 |
| P2093 | author name string | Brunhilde Wirth | |
| Eric Hahnen | |||
| Lars Brichta | |||
| P2860 | cites work | A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing | Q22008514 |
| Gemin8 is a novel component of the survival motor neuron complex and functions in small nuclear ribonucleoprotein assembly | Q24301969 | ||
| hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1 | Q24303882 | ||
| The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins | Q24316085 | ||
| A novel nuclear structure containing the survival of motor neurons protein | Q24324247 | ||
| Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism | Q24613087 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy | Q28177632 | ||
| Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy | Q28201294 | ||
| SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1 | Q28204721 | ||
| An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA | Q28204816 | ||
| Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1 | Q28206060 | ||
| Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients | Q28209134 | ||
| Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? | Q28214361 | ||
| What's up and down with histone deacetylation and transcription? | Q28238059 | ||
| The SMN complex | Q28259557 | ||
| Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells | Q28264072 | ||
| Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients | Q28291453 | ||
| Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons | Q28576647 | ||
| Identification and characterization of a spinal muscular atrophy-determining gene | Q29547495 | ||
| A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy | Q29617367 | ||
| An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). | Q33840923 | ||
| Treatment of spinal muscular atrophy by sodium butyrate | Q33933841 | ||
| Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy | Q34353103 | ||
| Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. | Q34398775 | ||
| The survival motor neuron protein in spinal muscular atrophy | Q34435656 | ||
| Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2) | Q35210565 | ||
| Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. | Q35943896 | ||
| A mouse model for spinal muscular atrophy | Q38316939 | ||
| The role of histone acetylation in SMN gene expression. | Q40437533 | ||
| Valproic acid increases SMN levels in spinal muscular atrophy patient cells. | Q40620622 | ||
| Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. | Q40741164 | ||
| Correlation between severity and SMN protein level in spinal muscular atrophy | Q41102726 | ||
| When is a deletion not a deletion? When it is converted | Q43105061 | ||
| The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy | Q43569750 | ||
| A clinical and genetic study of spinal muscular atrophy of adult onset: the autosomal recessive form as a discrete disease entity | Q48141545 | ||
| In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy | Q48485610 | ||
| Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. | Q48519096 | ||
| Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. | Q48586550 | ||
| Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation | Q57782739 | ||
| International SMA consortium meeting. (26-28 June 1992, Bonn, Germany) | Q67481178 | ||
| Genetic basis of adult-onset spinal muscular atrophy | Q71520123 | ||
| An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN | Q73295491 | ||
| A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy | Q73588971 | ||
| SMN oligomerization defect correlates with spinal muscular atrophy severity | Q74557706 | ||
| SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis | Q77421666 | ||
| SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN | Q81385781 | ||
| In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate | Q83139606 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | spinal muscular atrophy | Q580290 |
| muscular atrophy | Q2844600 | ||
| 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide | Q27216175 | ||
| P304 | page(s) | 101-10 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Human Genetics | Q5937167 |
| P1476 | title | The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells | |
| P478 | volume | 120 |
| Q42180894 | Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration. |
| Q26864605 | Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy |
| Q30493891 | CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy |
| Q40414569 | Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics. |
| Q38346151 | Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing |
| Q37154271 | Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy |
| Q37035709 | Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy |
| Q38546908 | Developing therapies for spinal muscular atrophy |
| Q33670661 | Development of histone deacetylase inhibitors as therapeutics for neurological disease |
| Q38014955 | Developments in the discovery of drugs for spinal muscular atrophy: successful beginnings and future prospects |
| Q28248304 | Differential regulation of the SMN2 gene by individual HDAC proteins |
| Q34172502 | Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development |
| Q58826477 | Drug discovery for spinal muscular atrophy |
| Q89477851 | Drug treatment for spinal muscular atrophy types II and III |
| Q30492560 | Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy |
| Q92513205 | Emerging roles of histone modifications and HDACs in RNA splicing |
| Q34760255 | Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds |
| Q37376101 | Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy |
| Q41457078 | Gestational Age-Dependent Increase of Survival Motor Neuron Protein in Umbilical Cord-Derived Mesenchymal Stem Cells |
| Q34792390 | High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics |
| Q28080593 | Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration |
| Q94544744 | Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation |
| Q26828876 | Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy |
| Q36599926 | Histone deacetylase inhibitors as therapeutics for polyglutamine disorders |
| Q28472268 | Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening |
| Q28254983 | Induction of full-length survival motor neuron by polyphenol botanical compounds |
| Q24647477 | Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing |
| Q33317280 | K+ channel regulator KCR1 suppresses heart rhythm by modulating the pacemaker current If. |
| Q46956989 | M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory |
| Q26752798 | Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy |
| Q37407855 | Multiple roles of HDAC inhibition in neurodegenerative conditions. |
| Q27321571 | Neuronal-specific deficiency of the splicing factor Tra2b causes apoptosis in neurogenic areas of the developing mouse brain |
| Q46825195 | Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy |
| Q35850907 | P-coumaric acid regulates exon 12 splicing of the ATP7B gene by modulating hnRNP A1 protein expressions |
| Q33836935 | Past, Present and Future Therapeutics for Cerebellar Ataxias |
| Q36924715 | Perspectives on clinical trials in spinal muscular atrophy |
| Q33786976 | Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells |
| Q28743986 | Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model |
| Q30743508 | Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. |
| Q61216219 | Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions |
| Q28271235 | SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy |
| Q40834224 | Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. |
| Q53288818 | Single molecule profiling of tau gene expression in Alzheimer's disease. |
| Q34582710 | Small molecules affecting transcription in Friedreich ataxia |
| Q34460251 | Spinal Muscular Atrophy Therapeutics: Where do we Stand? |
| Q26824894 | Spinal muscular atrophy: from gene discovery to clinical trials |
| Q34065993 | Splicing of the Survival Motor Neuron genes and implications for treatment of SMA |
| Q24655533 | Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition |
| Q41683448 | Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy |
| Q35821728 | Targeting Histone Deacetylases in Diseases: Where Are We? |
| Q34704344 | Targeting SR proteins improves SMN expression in spinal muscular atrophy cells |
| Q33830937 | The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy |
| Q35013439 | The importance of the SMN genes in the genetics of sporadic ALS. |
| Q37283454 | Therapeutic application of histone deacetylase inhibitors for central nervous system disorders |
| Q34296140 | Therapeutic strategies for the treatment of spinal muscular atrophy. |
| Q36158983 | Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice |
| Q58577889 | Using Systems Biology and Mathematical Modeling Approaches in the Discovery of Therapeutic Targets for Spinal Muscular Atrophy |
| Q34306857 | VPA response in SMA is suppressed by the fatty acid translocase CD36. |
Search more.